Perchlorate

Perchlorate

SCHEMBL3140978

Fc1ccc(-c2cccc(S)c2-c2ccc(F)cc2)cc1.[O-][Cl+3]([O-])([O-])O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.40
PTGS2 P35354 8/20 0.38
PTGS1 P23219 4/20 0.38
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
MAPK14 Q16539 2/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
LCK P06239 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
IGF1R P08069 1/20 0.33
MET P08581 1/20 0.33
PDGFRB P09619 1/20 0.33
FGFR1 P11362 1/20 0.33
PRKACA P17612 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5702366 0.91 ENPP1 (0.45) ENPP1PTGS2PTGS1SLC6A4SLC6A3
Bromide SCHEMBL3139909 0.89 ENPP1 (0.44) ENPP1PTGS2PTGS1SLC6A4SLC6A3
Perchlorate SCHEMBL3126960 0.84 ABL1 (0.40) ABL1RPS6KA3BCL2L1
Perchlorate SCHEMBL3132416 0.83 KIF11 (0.40) ENPP1KDRGSK3B
Perchlorate SCHEMBL3132388 0.83 PTGS2 (0.38) PTGS2PTGS1SLC6A4SLC6A3FGFR1
Perchlorate SCHEMBL3135944 0.83 ENPP1 (0.39) ENPP1PTGS2PTGS1KDRGPR84
Trifluoromethanesulfonic Acid SCHEMBL3130162 0.80 ENPP1 (0.42) ENPP1PTGS2PTGS1SLC6A4SLC6A3
Perchlorate SCHEMBL3135201 0.79 HDAC4 (0.46) ENPP1PTGS2PTGS1ABL1FGFR1
Perchlorate SCHEMBL3139518 0.79 GPR84 (0.36) GPR84
SCHEMBL3136615 0.77 PTGS2 (0.39) ENPP1PTGS2PTGS1SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642368-B2 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-05 US disclosed
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2007-04-12 US disclosed
EP-1676835-A1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT Wako Pure Chemical Industries, Ltd. (JP) 2006-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid ARSA, HAO2, HAO1 ENPP1 3425/4885PTGS2 1519/4885PTGS1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.